AU2008313294A1 - A diagnostic device for identifying rupture of membrane during pregnancy - Google Patents
A diagnostic device for identifying rupture of membrane during pregnancy Download PDFInfo
- Publication number
- AU2008313294A1 AU2008313294A1 AU2008313294A AU2008313294A AU2008313294A1 AU 2008313294 A1 AU2008313294 A1 AU 2008313294A1 AU 2008313294 A AU2008313294 A AU 2008313294A AU 2008313294 A AU2008313294 A AU 2008313294A AU 2008313294 A1 AU2008313294 A1 AU 2008313294A1
- Authority
- AU
- Australia
- Prior art keywords
- dry
- diagnostic device
- reagent
- reagents
- carrier matrices
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000012528 membrane Substances 0.000 title claims description 17
- 230000035935 pregnancy Effects 0.000 title description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 121
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 70
- 238000012360 testing method Methods 0.000 claims description 62
- 210000002700 urine Anatomy 0.000 claims description 59
- 239000010410 layer Substances 0.000 claims description 51
- 210000004381 amniotic fluid Anatomy 0.000 claims description 50
- 229940109239 creatinine Drugs 0.000 claims description 35
- 239000000126 substance Substances 0.000 claims description 31
- OBHRVMZSZIDDEK-UHFFFAOYSA-N urobilinogen Chemical compound CCC1=C(C)C(=O)NC1CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(CC3C(=C(CC)C(=O)N3)C)N2)CCC(O)=O)N1 OBHRVMZSZIDDEK-UHFFFAOYSA-N 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 239000000872 buffer Substances 0.000 claims description 20
- 238000006243 chemical reaction Methods 0.000 claims description 17
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 16
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 13
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 12
- 239000000123 paper Substances 0.000 claims description 12
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 11
- 239000002250 absorbent Substances 0.000 claims description 10
- 230000002745 absorbent Effects 0.000 claims description 10
- 239000011241 protective layer Substances 0.000 claims description 10
- 230000028327 secretion Effects 0.000 claims description 10
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 239000001913 cellulose Substances 0.000 claims description 8
- 229920002678 cellulose Polymers 0.000 claims description 8
- 229910021645 metal ion Inorganic materials 0.000 claims description 8
- -1 quaternary ammonium cations Chemical class 0.000 claims description 8
- KUQNCHZOCSYKOR-UHFFFAOYSA-N 1,1-dioxospiro[2,1$l^{6}-benzoxathiole-3,9'-xanthene]-3',4',5',6'-tetrol Chemical compound O1S(=O)(=O)C2=CC=CC=C2C21C1=CC=C(O)C(O)=C1OC1=C(O)C(O)=CC=C21 KUQNCHZOCSYKOR-UHFFFAOYSA-N 0.000 claims description 7
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 claims description 7
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- 239000004115 Sodium Silicate Substances 0.000 claims description 6
- 239000000853 adhesive Substances 0.000 claims description 6
- 230000001070 adhesive effect Effects 0.000 claims description 6
- 239000004202 carbamide Substances 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- 235000019795 sodium metasilicate Nutrition 0.000 claims description 6
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 claims description 6
- 229910052911 sodium silicate Inorganic materials 0.000 claims description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 6
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 claims description 5
- OORQUAGUOJMPCS-UHFFFAOYSA-N 4-[[4-(diethylamino)phenyl]diazenyl]benzenesulfonic acid Chemical compound C1=CC(N(CC)CC)=CC=C1N=NC1=CC=C(S(O)(=O)=O)C=C1 OORQUAGUOJMPCS-UHFFFAOYSA-N 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- 239000004816 latex Substances 0.000 claims description 5
- 229920000126 latex Polymers 0.000 claims description 5
- 229940012189 methyl orange Drugs 0.000 claims description 5
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 claims description 5
- HGPSVOAVAYJEIJ-XDHOZWIPSA-N 2-[(e)-(3,4-dihydroxyphenyl)-(3-hydroxy-4-oxoniumylidenecyclohexa-2,5-dien-1-ylidene)methyl]benzenesulfonate Chemical compound C1=CC(=O)C(O)=C\C1=C(C=1C(=CC=CC=1)S(O)(=O)=O)/C1=CC=C(O)C(O)=C1 HGPSVOAVAYJEIJ-XDHOZWIPSA-N 0.000 claims description 4
- 229920000742 Cotton Polymers 0.000 claims description 4
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- WWAABJGNHFGXSJ-UHFFFAOYSA-N chlorophenol red Chemical compound C1=C(Cl)C(O)=CC=C1C1(C=2C=C(Cl)C(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 WWAABJGNHFGXSJ-UHFFFAOYSA-N 0.000 claims description 4
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 claims description 4
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 4
- 239000003365 glass fiber Substances 0.000 claims description 4
- 229920005615 natural polymer Polymers 0.000 claims description 4
- 239000004745 nonwoven fabric Substances 0.000 claims description 4
- GVKCHTBDSMQENH-UHFFFAOYSA-L phloxine B Chemical compound [Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 GVKCHTBDSMQENH-UHFFFAOYSA-L 0.000 claims description 4
- 235000021317 phosphate Nutrition 0.000 claims description 4
- 239000002861 polymer material Substances 0.000 claims description 4
- 239000001508 potassium citrate Substances 0.000 claims description 4
- 229960002635 potassium citrate Drugs 0.000 claims description 4
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 4
- 235000011082 potassium citrates Nutrition 0.000 claims description 4
- 229910052709 silver Inorganic materials 0.000 claims description 4
- 239000004332 silver Substances 0.000 claims description 4
- 239000002023 wood Substances 0.000 claims description 4
- 239000002759 woven fabric Substances 0.000 claims description 4
- BCHIXGBGRHLSBE-UHFFFAOYSA-N (4-methyl-2-oxochromen-7-yl) dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C=CC2=C1OC(=O)C=C2C BCHIXGBGRHLSBE-UHFFFAOYSA-N 0.000 claims description 3
- YNXICDMQCQPQEW-UHFFFAOYSA-N 1-naphthyl dihydrogen phosphate Chemical compound C1=CC=C2C(OP(O)(=O)O)=CC=CC2=C1 YNXICDMQCQPQEW-UHFFFAOYSA-N 0.000 claims description 3
- JTNGEYANGCBZLK-UHFFFAOYSA-N 1h-indol-3-yl dihydrogen phosphate Chemical compound C1=CC=C2C(OP(O)(=O)O)=CNC2=C1 JTNGEYANGCBZLK-UHFFFAOYSA-N 0.000 claims description 3
- VVHIPDLBFRFFJT-UHFFFAOYSA-N 2-hydroxy-3-nitro-2-(3-nitrophenyl)propanoic acid Chemical compound [O-][N+](=O)CC(O)(C(=O)O)C1=CC=CC([N+]([O-])=O)=C1 VVHIPDLBFRFFJT-UHFFFAOYSA-N 0.000 claims description 3
- ZXVONLUNISGICL-UHFFFAOYSA-N 4,6-dinitro-o-cresol Chemical group CC1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O ZXVONLUNISGICL-UHFFFAOYSA-N 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- WZRZTHMJPHPAMU-UHFFFAOYSA-L disodium;(3e)-3-[(4-amino-3-sulfonatophenyl)-(4-amino-3-sulfophenyl)methylidene]-6-imino-5-methylcyclohexa-1,4-diene-1-sulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(=N)C(C)=CC1=C(C=1C=C(C(N)=CC=1)S([O-])(=O)=O)C1=CC=C(N)C(S(O)(=O)=O)=C1 WZRZTHMJPHPAMU-UHFFFAOYSA-L 0.000 claims description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 3
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 229960002816 potassium chloride Drugs 0.000 claims description 3
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 claims description 3
- 239000001230 potassium iodate Substances 0.000 claims description 3
- 235000006666 potassium iodate Nutrition 0.000 claims description 3
- 229940093930 potassium iodate Drugs 0.000 claims description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 3
- 229940093916 potassium phosphate Drugs 0.000 claims description 3
- 235000011009 potassium phosphates Nutrition 0.000 claims description 3
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims description 3
- 229910052939 potassium sulfate Inorganic materials 0.000 claims description 3
- 229940093914 potassium sulfate Drugs 0.000 claims description 3
- 235000011151 potassium sulphates Nutrition 0.000 claims description 3
- GKAMNGMEOQWSHF-UHFFFAOYSA-L potassium;sodium;chloride;hydroxide Chemical compound [OH-].[Na+].[Cl-].[K+] GKAMNGMEOQWSHF-UHFFFAOYSA-L 0.000 claims description 3
- CIJQGPVMMRXSQW-UHFFFAOYSA-M sodium;2-aminoacetic acid;hydroxide Chemical compound O.[Na+].NCC([O-])=O CIJQGPVMMRXSQW-UHFFFAOYSA-M 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
- 239000000920 calcium hydroxide Substances 0.000 claims description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 2
- YEAOVYLCHBNHNT-UHFFFAOYSA-N 1,2-dinitro-3-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC=CC(C(F)(F)F)=C1[N+]([O-])=O YEAOVYLCHBNHNT-UHFFFAOYSA-N 0.000 claims 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 238000000034 method Methods 0.000 description 38
- 239000011159 matrix material Substances 0.000 description 36
- 239000000975 dye Substances 0.000 description 28
- 239000000243 solution Substances 0.000 description 18
- 210000004379 membrane Anatomy 0.000 description 14
- 239000000203 mixture Substances 0.000 description 11
- 230000008859 change Effects 0.000 description 10
- 239000012530 fluid Substances 0.000 description 10
- 238000003556 assay Methods 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 239000007793 ph indicator Substances 0.000 description 9
- 210000003756 cervix mucus Anatomy 0.000 description 6
- 206010066470 Amniorrhoea Diseases 0.000 description 5
- 239000012491 analyte Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- GQOKIYDTHHZSCJ-UHFFFAOYSA-M dimethyl-bis(prop-2-enyl)azanium;chloride Chemical compound [Cl-].C=CC[N+](C)(C)CC=C GQOKIYDTHHZSCJ-UHFFFAOYSA-M 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 210000002219 extraembryonic membrane Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 230000003319 supportive effect Effects 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VYWYYJYRVSBHJQ-UHFFFAOYSA-N 3,5-dinitrobenzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1 VYWYYJYRVSBHJQ-UHFFFAOYSA-N 0.000 description 2
- JCYPECIVGRXBMO-UHFFFAOYSA-N 4-(dimethylamino)azobenzene Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=CC=C1 JCYPECIVGRXBMO-UHFFFAOYSA-N 0.000 description 2
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- OBRMNDMBJQTZHV-UHFFFAOYSA-N cresol red Chemical compound C1=C(O)C(C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(C)C(O)=CC=2)=C1 OBRMNDMBJQTZHV-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000009928 pasteurization Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- MKWJZTFMDWSRIH-UHFFFAOYSA-N (4-fluoro-3-nitrophenyl)methanol Chemical compound OCC1=CC=C(F)C([N+]([O-])=O)=C1 MKWJZTFMDWSRIH-UHFFFAOYSA-N 0.000 description 1
- GWGBNENHEGYJSN-UHFFFAOYSA-N 2,4-dinitrobenzenesulfonic acid;hydrate Chemical compound O.OS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O GWGBNENHEGYJSN-UHFFFAOYSA-N 0.000 description 1
- MDGFKZKMIQQRPU-UHFFFAOYSA-N 2-bromo-4-[3-(3-bromo-5-chloro-4-hydroxyphenyl)-1,1-dioxo-2,1$l^{6}-benzoxathiol-3-yl]-6-chlorophenol Chemical compound C1=C(Br)C(O)=C(Cl)C=C1C1(C=2C=C(Br)C(O)=C(Cl)C=2)C2=CC=CC=C2S(=O)(=O)O1 MDGFKZKMIQQRPU-UHFFFAOYSA-N 0.000 description 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- AXDJCCTWPBKUKL-UHFFFAOYSA-N 4-[(4-aminophenyl)-(4-imino-3-methylcyclohexa-2,5-dien-1-ylidene)methyl]aniline;hydron;chloride Chemical compound Cl.C1=CC(=N)C(C)=CC1=C(C=1C=CC(N)=CC=1)C1=CC=C(N)C=C1 AXDJCCTWPBKUKL-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- FZRCKLPSHGTOAU-UHFFFAOYSA-N 6-amino-1,4-dimethylcyclohexa-2,4-diene-1-carbaldehyde Chemical compound CC1=CC(N)C(C)(C=O)C=C1 FZRCKLPSHGTOAU-UHFFFAOYSA-N 0.000 description 1
- FYEHYMARPSSOBO-UHFFFAOYSA-N Aurin Chemical compound C1=CC(O)=CC=C1C(C=1C=CC(O)=CC=1)=C1C=CC(=O)C=C1 FYEHYMARPSSOBO-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 239000004214 Fast Green FCF Substances 0.000 description 1
- 102000008015 Hemeproteins Human genes 0.000 description 1
- 108010089792 Hemeproteins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000036818 High risk pregnancy Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102100027636 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 1
- 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 description 1
- 238000007696 Kjeldahl method Methods 0.000 description 1
- 238000013494 PH determination Methods 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036603 Premature rupture of membranes Diseases 0.000 description 1
- QPMIVFWZGPTDPN-UHFFFAOYSA-N Tetrabromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C(C(Br)=C(Br)C(Br)=C2Br)=C2S(=O)(=O)O1 QPMIVFWZGPTDPN-UHFFFAOYSA-N 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- DGOBMKYRQHEFGQ-UHFFFAOYSA-L acid green 5 Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 DGOBMKYRQHEFGQ-UHFFFAOYSA-L 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
- 229940052223 basic fuchsin Drugs 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- NUHCTOLBWMJMLX-UHFFFAOYSA-N bromothymol blue Chemical compound BrC1=C(O)C(C(C)C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C(=C(Br)C(O)=C(C(C)C)C=2)C)=C1C NUHCTOLBWMJMLX-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 108010054169 dextrostix Proteins 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 1
- 235000019240 fast green FCF Nutrition 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 201000001505 hemoglobinuria Diseases 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 239000000852 hydrogen donor Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- DZVCFNFOPIZQKX-LTHRDKTGSA-M merocyanine Chemical group [Na+].O=C1N(CCCC)C(=O)N(CCCC)C(=O)C1=C\C=C\C=C/1N(CCCS([O-])(=O)=O)C2=CC=CC=C2O\1 DZVCFNFOPIZQKX-LTHRDKTGSA-M 0.000 description 1
- CEQFOVLGLXCDCX-WUKNDPDISA-N methyl red Chemical compound C1=CC(N(C)C)=CC=C1\N=N\C1=CC=CC=C1C(O)=O CEQFOVLGLXCDCX-WUKNDPDISA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- HXHCOXPZCUFAJI-UHFFFAOYSA-N prop-2-enoic acid;styrene Chemical compound OC(=O)C=C.C=CC1=CC=CC=C1 HXHCOXPZCUFAJI-UHFFFAOYSA-N 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 210000005227 renal system Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Absorbent Articles And Supports Therefor (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Description
WO 2009/050711 PCT/IL2008/001371 A DIAGNOSTIC DEVICE FOR IDENTIFYING RUPTURE OF MEMBRANE DURING PREGNANCY 5 Field of the invention The present invention relates to diagnostic methods and devices. More particularly, the present invention relates to diagnostic test and devices for identification of membrane rupture during pregnancy. 10 Background of the invention Labor is different for every woman, and it can be difficult to pinpoint the 15 moment when it begins. Rather than a single event, it is an entire process, with several physiological changes and events occurring in the body that combine to eventually deliver a baby. One of those changes or events is the rupture of the membrane surrounding the baby in the uterus; which is usually a clear indication that labor is imminent. The rupture of the membrane 20 happens sometimes abruptly and obviously, with a copious flow of amniotic fluid. But often, a pregnant woman may have a ruptured membrane and be very uncertain or unaware whether the membrane has been really ruptured. There are two main reasons for this. First, the baby's head may act as a cork at the opening of the uterus and so, instead of gushing out, the 25 amniotic fluid will only be slowly released. Moreover, amniotic fluid may leak out drop by drop from a tiny opening of the uterus, and the pregnant woman may not feel the first contractions until hours later. Secondly, in late pregnancy, women often have difficulty controlling their urination. Because of this, a gradual flow of amniotic fluid from the vagina will not be noticed when 30 the woman is accustomed to having small amounts of urine escape involuntarily from time to time.
WO 2009/050711 PCT/IL2008/001371 2 Wrong and untimely diagnosis of amniotic fluid leakage, especially in high-risk pregnancies, can result in failure to implement proper treatment, which increases the risk to the pregnant women and her fetus. Risks of neonatal consequences of unnoticed amniotic fluid leakage include fetal 5 distress, infection and preterm delivery and can lead to very dangerous sequels for both the mother and fetus. Currently, the only available way for a pregnant woman to detect at home amniotic fluid is achieved by using an expensive panty liner self-testing diagnostic kit. Thus, almost all pregnant women choose to visit their io physicians or the emergency room in a hospital. At the hospital, the tests available today for the identification of amniotic fluid are invasive, indecisive, or expensive and in any case lead to discomfort for the patient. There is a need to greatly reduce the likelihood of membrane rupture being unnoticed at home by using an accurate, fast and inexpensive device that can act also as a 15 tool for the physician to manage the test at the clinic/hospital. Prior art Among several conventional methods available today by physicians, a 20 few examples are described herein. The most widespread method for urine composition analysis is by using a technique known as a "dip-and-read test strip" or "dipstick". A dipstick is an assay strip that is made up of chemical reagents bonded to a reagent carrier matrix (pad) on a strip. Usually, the strip itself is formed from polymeric materials such as polyethylene, polycarbonate 25 or polystyrene. Each carrier matrix has a different reagent in it. This dipstick is dipped into a urine sample and removed. Upon contact between the reagents imbedded in the matrices and the urine sample, color reactions occur. A dipstick can be designed either as a single pad test strip (for the assay of one analyte) or as a multiple pad test strip (for the assay of several different 30 analytes all together). Dipstick can be used manually or with the appropriate chemistry analyzer. Multiple profile reagent strip for simultaneously or WO 2009/050711 PCT/IL2008/001371 3 sequentially performing multiple analyses of analyte is disclosed in U.S. Pat. Nos. 4,595,439, 4,526,753, 4,160,008 3,123,443, 3,212,855, 3,814,668, 4,038,485, 3,531,254. Several such test devices are available in the market. The following is a 5 partial list of dipstick trademarks CLINISTIX, MULTISTIX, KETOSTIX, N MULTISTIX, DIASTIX, DEXTROSTIX, AUTION STICKS, CHEMSTRIP. The reagent carrier matrix is usually an absorbent material which allows the liquid sample to move through the matrix. This movement of liquid sample is in response to capillary forces formed in the matrix. During the io movement of the liquid through the matrix, it contacts the chemical reagent composition impregnate in the matrix. Thereafter, detectable and measurable color transition occurs. If the dipstick can measure several analytes simultaneously, the color change in each reagent carrier matrix can be correlated to the amount of different analyte in the liquid sample. Manual 15 analysis of the results requires comparison of the color development of the test on the dipstick to a color chart. The reagent carrier matrix material can be of any substance that can incorporate the chemical reagents necessary to carry out the assay of interest. The preferable matrix should be inert with respect to the chemical 20 reagents and should not alter the sample or the test results. Reagent carrier matrices can be made of many materials, some of these materials are: fiber containing papers such as filter papers, woven and nonwoven fabrics, synthetic or modified natural polymers, sponge materials, cellulose, glass fiber, microporous membranes, and wood. The reagent matrix can also differ 25 in regards to roughness and smoothness together with softness and hardness. The following list of patents describe the use of different matrices: U.S. Pat. Nos. 3,846,247, 3,552,928, 3,802,842, 3,418,083. Sewell DL, et al. discusses, among other things, the cost of using the dipstick as a screening method for urinalysis in a scientific paper published in 30 the American Journal of Clinical Pathology Vol. 83 (6) pages 740-743, 1985. The authors state that using a dipstick procedure "cost approximately $0.76 for reagents". Various devices are described in the literature for the WO 2009/050711 PCT/IL2008/001371 4 determination of particular urinary analytes with the use of reagent carrier matrices (filter paper, microcapsules, dipstick, etc.). The following list of assay devices utilizing prior art includes dry tablets, dipsticks, or other techniques for the analysis urinary constituents. U.S. patent no. 4,147,514 describe the 5 detection of ketone bodies; U.S. Pat. no. 3,146,070 discloses chemical compositions in dry form on a carrier (dipstick) impregnated with a pH indicator for the determination of pH. Methods, composition, and test device for determining the ionic strength or specific gravity of a test sample such as urine are disclosed in the following U.S. patents: 4,318,709, 5,403,744. 10 Jaffe method is a widely known method for the determination of creatinine. This method involves formation of orange-red color with an alkaline picrate solution. U.S. pat. no. 6,001,656 discloses a device for the assay of creatinine in fluid test samples. The improvement in this patent involves the inclusion of one or more selected quinolines in the reagent formulation. 15 Another method for creatinine determination is described by Benedict and Behre in the Journal of Biological Chemistry (1936) which involves the reaction of 3,5-dinitrobenzoic acid with creatinine in an alkaline medium. Other methods, composition, and test devices for determining creatinine in a liquid sample such as urine are disclosed in the following U.S. patents: 4,215,197 20 (using an enzymatic composition), 5,662,867, 5,733,787. Suitable materials for the detection of creatinine include picric acid, 3,5-dinitrobenzoic acid, 3,4 dinitrobenzoic acid, 2,4-dinitrobenzene sulfonic acid, (3,5-dinitrobenz)yl alcohol, (3,5-dinitrobenzo)-nitrile, (3,5-dinitrobenz)amide and N,N-diethyl-(3,5 dinitrobenz)amide. 25 Different methods for protein determination in fluid have been reported. These methods include the Biuret method, Lowry method, Kjeldahl method, dyestuff combination method, fluorometric method and UV method. Of these methods, the Kingbury-Clark method; reported in J. Lab. Clin. Med., 11, 981 (1926) and the Meulemans method; reported in Clin. Chim. Acta, 5, 757 30 (1960) and the Coomassie brilliant blue method; reported in Anal. Biochem. 72, 248 (1967) are widely used. The Bradford dye assay for protein determination, U.S. Pat. no. 4,023,933, is also used routinely in almost every WO 2009/050711 PCT/IL2008/001371 5 biochemical laboratory. Generally, protein interacts with substances, principally with dyes such as coomassie brilliant blue, bromphenol blue (tetrabromophenol blue), and eosine as well as metal ions such as copper (II), lead (II) zinc (ll)and silver (1). The addition of protein-containing solution to the 5 reaction between a dye and a metal ion gives a spectral change to a dye metal ion solution. More protein indicators include those described as well as the merocyanine and nitro or nitroso substituted polyhalogenated phenolsulfonephthaleins disclosed in U.S. Pat. no. 5,279,790. Other protein indicators are Fast Green FCF, Light Green SF, pyrogallol red and 10 pyrocatechol violet, bromochlorophenol blue (3',3"-dibromo-5',5" dichlorophenolsulfonephthalein), basic fuchsin, basic violet, martius yellow, phloxine B, methyl yellow, congo red, methyl orange and ethyl orange (4-(4 diethylaminophenylazo)benzenesulfonic acid). The following list of U.S. patents concern with measurement of protein in solution, such as urine, using 15 reagent systems usable in the dipstick method: 5,424,215, 5,593,895, 6,815,210, 4,960,710, 3,485,587, 5,087,575, 4,023,933. Various dipsticks used for urine testing contain tests for urobilinogen. CHEMSTRIP of Roch diagnostics, and MULTISTIX of Bayer diagnostics are typical examples of such products which include tests for urobilinogen. The 20 classical urobilinogen test, developed by Paul Ehrlich in 1901, employs paradimethylaminobenzaldehyde as a test for which in strongly acid medium produces a brown-orange-red color with Ehrlich's reagent. More background on urobilinogen, Ehrlich reaction and urobilinogen testing is described in, Tietz, Textbook of Clinical Chemistry, W. B. Saunders Company. Examples of 25 U.S. patents and dipsticks for the determination of urobilinogen based on Ehrlich's reaction and the diazonium coupling reaction are: US Pat. nos. 3,853,466, 3,630,680, 4,665,038, 4,290,771, 3,989,462, 3,814,586. More U.S. patents concern with measurement of urobilinogen in solution, such as urine, using reagent systems usable in the dipstick method are: 4,158,546 and 30 3,447,905. The earliest method of alkaline phosphatase test was introduced by Kay in 1930. Later, a popular assay method for the determination of alkaline WO 2009/050711 PCT/IL2008/001371 6 phosphatase using p-nitrophenyl phosphate introduced in 1946 by Bessey, Lowry and Brock. This method relays on the fact that after exposure to fluids containing alkaline phosphatase, the colorless p-nitrophenyl phosphate is catalytically hydrolyzed into a yellow colored product p-nitrophenol (and 5 phosphate). Thus, the concentration of the enzyme is determined by following the increased intensity of the yellow color of the reaction's product. Alkaline phosphatase activity is naturally present in raw milk, whereas after pasteurization, the enzyme is denatured. So, alkaline phosphatase activity is used as an indicator for proper milk pasteurization. One such dry test of io alkaline phosphatase activity in milk is PHOSPHATESMO MI, manufactured by MACHEREY-NAGEL GmbH & Co. The presence of hemoglobin in urine is called hemoglobinuria, such a condition can occur as a result of lysis of red blood cells (RBS) in the urinary tract. The term hematuria is used when intact RBS are present in the urine. 15 This condition can occur in bleeding in the renal or genitourinary systems. The most widely used tests for the detection of blood in urine or feces depend on the fact that the heme proteins can act as peroxidases. This reaction requires a hydrogen donor molecule. Typical examples of products that include tests for blood detection are MULTISTIX 10SG, HEMOCCULT 11, and AUTION 20 STICKS. More recently, United States Patent 4,357,945, issued on Nov. 9, 1982 to Janco for DEVICE FOR TESTING AND RUPTURING AMNIOTIC MEMBRANE, describes a finger-engaging device provided with a pH indicator. Upon exposure to fluids, the indicator changes color if the amniotic 25 membrane has ruptured. United States Patent 5,425,377, issued on Jun. 20, 1995 to Caillouette for PH MEASUREMENT OF BODY FLUID, describes a swabbing structure on a stick, provided with a pH indicator for the measurement of vaginal fluid pH. Several other methods are provided in the following: United States 30 Patent 5,554,504 issued on Sep. 10, 1996 to Rutanen for DIAGNOSTIC METHOD FOR DETECTING THE RUPTURE OF FETAL MEMBRANES, describes the detection of insulin-like growth factor binding protein 1 in a WO 2009/050711 PCT/IL2008/001371 7 vaginal secretion sample. United States Patent 5,281,522, issued on Jan. 25, 1994 to Senyei et al. for REAGENTS AND KITS FOR DETERMINATION OF FETAL FIBRONECTIN IN A VAGINAL SAMPLE, describes kits for detection of rupture of membranes by sampling from the vaginal cavity and exposing it 5 to antibodies such as anti-fetal fibronectin antibody and an anti-fibronectin antibody. United States Patent 5,096,830, issued on Mar. 17, 1992 to Senyei et al. for PRETERM LABOR AND MEMBRANE RUPTURE TEST describes a method for determining fetal membrane rupture by removing a sample from the vaginal cavity and contacting it with an insoluble support to which anti-fetal io antigen antibody is adhered, and the fetal antigen binding to the support is determined. Several devices involving panty shields or tampons with pH indicators are known. Following here are examples of some of these patents: United States Patent 6,149,590 issued on Nov. 21, 2000 to Smith et al. for SYSTEM is FOR IDENTIFYING PREMATURE RUPTURE OF MEMBRANE DURING PREGNANCY describes a pad having an upper outer layer, a lower outer layer, and an intermediate pH-responsive component. United States Patents 6,921,647 and 6,627,394 issued to Kritzman et al. for SECRETION MONITORING ARTICLE and DIAGNOSTIC PAD describes pads with pH 20 sensitive indicators for the detection of amniotic fluid leakage. United States Patent 5,217,444 issued to Schoenfeld for ABSORBENT TAMPON demonstrates an absorbent material containing a pH indicator material indicating by a color change the acidity or alkalinity of a liquid coming into contact with it. 25 It should be mentioned that tests that measure only the pH of the vaginal secretion for the differentiation of amniotic fluid from urine are not accurate due to the following: 1) The pH of urine may vary from 4.5 to 8 depending on the kidneys homeostatic activity and water intake, and 2) The pH of amniotic fluid ranges from 6.9 to 7.15 in late pregnancy. This 30 overlapping range of pH can lead to false diagnosis that may cause medical complications.
WO 2009/050711 PCT/IL2008/001371 8 Immunochromatographic tests which are based on antibodies detecting specific proteins in the amniotic fluid or urine, are not commonly available to the general public mainly because of high price due to the monoclonal/polyclonal antibodies which they contains. Generally, Enzymatic 5 methods are also expensive due to the high cost of enzyme production. Summary of the present invention 10 It is an object of the present invention to provide unique devices and methods for differentiating of amniotic fluid from urine that are based on analyzing more then one analyte using dry chemical reactions without the need of enzymatic or immunology methods. It is another object of the present invention to provide unique devices 15 and methods for differentiating of amniotic fluid from urine that are simple and are of money and time-saving nature that ultimately help solve the dilemma of whether labor may soon begin or not. A woman or a medical caretaker will be able to observe immediately after the first drop of leaking liquid meets the device, whether it contains amniotic fluid or urine. 20 It is yet another object of the present invention to provide unique devices and methods for differentiating of amniotic fluid from urine that can be used with pregnant female subjects either human or non-human. Determining the onset of labor in non-human females can be even more unpredictable due to the inability of the animal to discuss its condition. 25 In addition, another object of the present invention is the point of care practice of rapid chemical analysis of biological fluids such as urine, saliva, sweat, cerebrospinal fluid (CSF), milk or fluids from other sources. It is therefore provided in accordance with a preferred embodiment of 30 the present invention a dry diagnostic device for distinguishing between amniotic fluid and urine in female secretion, the dry diagnostic device comprising: WO 2009/050711 PCT/IL2008/001371 9 a base layer; at least two inert carrier matrices provided on said base layer; dry reagents provided on said at least two inert carrier matrices wherein said dry reagents are capable of forming a 5 chemical reaction with substances in the female secretion so as to visually distinguishing between the amniotic fluid and urine wherein said dry reagents in each of said at least two carrier matrices is capable of reacting with different substance of said substances. Furthermore and in accordance with yet another preferred embodiment io of the present invention, said at least two carrier matrices are made of absorbent material selected from a group of materials such as fiber-containing papers, woven and non-woven fabrics, synthetic or modified natural polymers, sponge materials, cellulose, glass fiber, micro-porous membranes, wood, micro porous polymer materials such as styrene based copolymer, latex 15 based, cellulose based or cotton based matrices. Furthermore and in accordance with yet another preferred embodiment of the present invention, said dry reagents are capable of reacting with substances present in the amniotic fluid or in the urine, wherein the substances have concentration markedly higher in one of the amniotic fluid or 20 urine than their concentration in the former. Furthermore and in accordance with yet another preferred embodiment of the present invention, said substances include substances such as creatinine, alkaline phosphatase, total protein, urea, urobilinogen and blood. Furthermore and in accordance with yet another preferred embodiment 25 of the present invention, one of the dry reagents in one of said at least two carrier matrices is capable of reacting with creatinine. Furthermore and in accordance with yet another preferred embodiment of the present invention, said one of the carrier matrices comprises two reagent layers; one of which contains creatinine sensitive dye fixed with a dye 30 fixing agent and a second one containing a buffer capable of keeping said one of the test zones in a relatively high pH value.
WO 2009/050711 PCT/IL2008/001371 10 Furthermore and in accordance with yet another preferred embodiment of the present invention, said one of the carrier matrices comprises a unique layer containing a creatinine sensitive dye, buffer, and dye fixing agent. Furthermore and in accordance with yet another preferred embodiment 5 of the present invention, said creatinine sensitive dye is selected from a group of dinitro derivatives such as 3'5'-dinitrobenzoic acid, 2'4'-dinitrobenzoic acid, 3'5'- dinitrobenzotrifluoride, 3'5'-dinitrobenzamide, 3'5'-dinitrobenzoyl- phenyl glycine, 3,5-dinitrohydroxyphenylpropionic acid. Furthermore and in accordance with yet another preferred embodiment 10 of the present invention, said dye fixing agent selected from polymerized quaternary ammonium cations (quats) such as polydiallyldimethylammoniumchloride, polymonoallyltrimethylammoniumchloride, polytrimethylaminoethylmethacrylatechoride, 15 polyvinylbenzyltrimethylammoniumchloride, polyvinylmpthylpyridine- chloride. Furthermore and in accordance with yet another preferred embodiment of the present invention, said creatinine sensitive dye and said dye fixing agent are buffered so as to keep a stable pH in a range of about 9 to 13.5. Furthermore and in accordance with yet another preferred embodiment 20 of the present invention, a buffer is selected from a group of sodium metasilicate, sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium hydroxide-potassium chloride, potassium carbonate, glycine - sodium hydroxide, and sodium borate. Furthermore and in accordance with yet another preferred embodiment 25 of the present invention, one of the dry reagents in one of the carrier matrices is capable of reacting with total protein. Furthermore and in accordance with yet another preferred embodiment of the present invention, said one of the dry reagents is a dye selected from a group of 3',3",5',5"-Tetrabromophenolsulfonephthalein, coomassie brilliant 30 blue, Fast Green, Light Green, Pyrogallolsulfonephthalein (pyrogallol red), Pyrocatecholsulfonphthalein (Pyrocatechol Violet), 3',3"-Dibromo-5',5"- WO 2009/050711 PCT/IL2008/001371 11 dichlorophenolsulfonephthalein, Fuchsin acid, 2,4-Dinitro-1 -naphthol (martius yellow) phloxine B, congo red, ethyl orange and methyl orange. Furthermore and in accordance with yet another preferred embodiment of the present invention, the device further comprising a buffer such as 5 potassium citrate, potassium chloride, potassium sulfate, potassium iodate or potassium phosphate. Furthermore and in accordance with yet another preferred embodiment of the present invention, the device further comprising metal ion selected from Copper, lead, Zink, Silver. 10 Furthermore and in accordance with yet another preferred embodiment of the present invention, one of the dry reagents in one of the carrier matrices is capable of reacting with alkaline phosphatase. Furthermore and in accordance with yet another preferred embodiment of the present invention, said one of the dry reagents Alkaline phosphates' 15 substrate selected from p-nitrophenyl phosphate, indoxyl phosphate, 4 methylumbelliferyl phosphate and alpha-naphthyl-phosphate. Furthermore and in accordance with yet another preferred embodiment of the present invention, one of said dry reagents is a pH sensitive reagent. Furthermore and in accordance with yet another preferred embodiment 20 of the present invention, said dry reagents cannot exit the carrier matrices. Furthermore and in accordance with yet another preferred embodiment of the present invention, said at least two carrier matrices are covered by a protective layer. Furthermore and in accordance with yet another preferred embodiment 25 of the present invention, said protective layer is transparent. Furthermore and in accordance with yet another preferred embodiment of the present invention, said protective layer can be made of a thin "one-way structure" membrane permeable to liquids flowing to said at least two carrier matrices and prevents flow of reagents outwardly from the device. 30 Furthermore and in accordance with yet another preferred embodiment of the present invention, a sticky backing layer is provided beneath said base layer.
WO 2009/050711 PCT/IL2008/001371 12 Furthermore and in accordance with yet another preferred embodiment of the present invention, said sticky backing layer is adjacently provided with an outer protective layer. Furthermore and in accordance with yet another preferred embodiment 5 of the present invention, said at least two carrier reagent matrices are organized in substantially parallel lines. Furthermore and in accordance with yet another preferred embodiment of the present invention, said at least two reagent carrier matrices are organized in concentric lines. 10 In addition and in accordance with yet another preferred embodiment of the present invention, said at least two reagent carrier matrices are surrounded by adhesive material so as to allow adhering the diagnostic device when said at least two test zones are opposite a vaginal canal of a female animal. 15 Brief description of the figures Some embodiments of the invention are herein described, by way of 20 example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only, and are presented in the cause of providing what is believed to be the most useful and readily 25 understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in 30 practice. In the drawings: WO 2009/050711 PCT/IL2008/001371 13 Figure 1 illustrates a cross sectional view of the diagnostic device in accordance with a preferred embodiment of the present invention. 5 Figures 2-5 illustrate diagnostic devices for adhering onto women panties in accordance with preferred embodiments of the present invention. Figures 6a-d illustrate diagnostic pads in accordance with preferred embodiments of the present invention. 10 Figure 7 illustrates a veterinary diagnostic pad in accordance with another preferred embodiment of the present invention. 15 Detailed description of the invention Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details set forth in the following description or exemplified by the 20 Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways. The terms "comprises", "comprising", "includes", "including", and "having" together with their conjugates mean "including but not limited to" The term "consisting of' has the same meaning as "including and 25 limited to". The term "consisting essentially of' means that the composition, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or 30 structure. As used herein, the singular form "a", "an" and "the" include plural references unless the context clearly dictates otherwise. For example, the WO 2009/050711 PCT/IL2008/001371 14 term "a compound" or "at least one compound" may include a plurality of compounds, including mixtures thereof. Throughout this application, various embodiments of this invention may be presented in a range format. It should be understood that the description in 5 range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub-ranges as well as individual numerical values within that range. 10 It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub 15 combination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements. The present invention provides unique and novel devices to distinguish 20 amniotic fluids from urine in a simple and fast manner so as to allow a pregnant woman to know her pregnancy condition. According to one aspect of the present invention, a device that resembles an 'adhesive plaster', which is a disposable strip containing sensitive chemical indicators, is used during last months of pregnancy. The strip is relatively small in its dimensions and 25 comprises at least two layers; an adhesive backing and an absorbing material containing the indicators. The woman using the device simply adheres it to her panties with the test zones facing up towards the body. In case the woman uses panty liner, she can place the strip on top of it. The rapid chemical reactions in the test zones of the device cause a distinct color 30 change in the case of amniotic fluid leakage and a clearly different color change when urine has contacted the test zones. The device of the present invention acts as a diagnostic tool to allow the customer to detect whether the WO 2009/050711 PCT/IL2008/001371 15 secretion contains amniotic fluid or only urine, according to a known color index supplied with the device. According to a second aspect of the present invention, a device resembling a pad containing sensitive indicators is used independently of 5 contacting the woman body. This device can be used by pressing it against wet underwear or a wet panty liner after leakage of fluids has been noticed. This will cause the reagents in the reagent carrier matrices to come in contact with the body fluids and almost immediately after the leaking liquid meets the diagnostic device, chemical reactions occur in the reagent carrier matrices io and cause a color change. Again, the woman (or caregiver) using this device will be able to see whether the liquid contains amniotic fluid or only urine, according to a known color index supplied with the device. In accordance with a third aspect of the present invention, a device that resembles a panty-liner is containing the sensitive indicators that allow the 15 distinction between amniotic fluid and urine. The pregnant woman will attach this product to her underwear and will get on with her day. The indicator reagent areas should be positioned directly opposite the vagina. This way, the sensitive panty-liner will be in a close contact with the woman body fluids. In all aspects of the invention, if storage is needed following collection, 20 the sample can be transferred to a suitable container for storage. Alternatively, immediate processing of the sample can be performed. If used, the sample is placed directly on the reagent carrier matrices of the device and testing is performed within minutes of sample collection. In accordance with another aspect of the present invention, a 25 veterinary device is provided. The device containing the sensitive reagents will be directly attached to a non-human female vagina opening. This may be achieved simply by a bandage design in which the adhesive zone is around or on the sides of the reagent carrier matrices test zone. Thus, a close contact with the animal body fluids will be achieved. Using a device without direct 30 contact with the animal body can also be achieved by obtaining a fluid sample with a swab having a fibrous tip or by suction or lavage device, and applying it to the indicators areas on the device.
WO 2009/050711 PCT/IL2008/001371 16 In accordance with a preferred embodiment of the present invention, the determination whether amniotic fluid or urine is present in the woman's secretion relies upon several non-enzymatic and non-immunological separated reactions that can be determined as associated with either urine or 5 amniotic fluid by their distinguished color. In most of the tests available today for the identification of the cause of wetness during pregnancy, concentration difference of only one analyte in urine or amniotic fluid is measured. In the present invention, the existence of at least two of the following substances: protein, creatinine, urea, urobilinogen, blood, and alkaline phosphatase are io identified as well as pH. Basically, it was identified that protein and alkaline phosphatase are present in higher concentrations in amniotic fluid relative to urine while creatinine, urea and urobilinogen are present in higher concentrations in urine relative to amniotic fluid. Blood may exist in amniotic fluid in higher concentration than in normal urine. Chemicals that can be used 15. in order to distinguish between the fluids in accordance with a preferred embodiment of the present invention are ones that upon binding or reacting with one of the substances indicated herein or act upon a certain environment undergo a change in spectroscopic properties. Therefore, diagnostic device that comprises reagent carrier matrices 20 provided with chemical indicators according to the present invention is capable of detecting at least two of the following substances: protein, creatinine, urobilinogen, urea, blood, and alkaline phosphatase as well as pH value. The method of the present invention is based on the following facts 1) The concentration of total protein in amniotic fluid is normally substantially 15 25 times higher than its concentration in urine, 2) The concentration of creatinine and urobilinogen in urine is normally about 10 times more than their concentration in amniotic fluid, and 3) The concentration of urea in urine is normally more than 2 times its concentration in amniotic fluid, 4) The concentration of alkaline phosphatase in amniotic fluid is normally more than 7 30 times higher than the concentration in urine, 5) During rupture of the fetal membranes, the amniotic fluid coming out may contain blood, which is in contrast to urine of healthy woman. Therefore, even if a small amount of WO 2009/050711 PCT/IL2008/001371 17 amniotic fluid is present in vaginal secretion and comes in contact with a pad of the present invention, the pad allows the diagnostic of fetal membrane rupture with an extremely high accuracy. Other substances with similar concentration differences may also be detected. 5 The present invention is further illustrated by the following examples of devices provided with sensitive indicators for the detection and distinction of urine or amniotic fluid leakage. Reference is made to Figure 1 illustrating a diagnostic device in accordance with a preferred embodiment of the present invention, in an upper io view and cross sectional view, respectively. A device 10 has at least two, and preferably several reagent carrier matrices 12. Figure 1 illustrates a device that is adapted to be attached to the woman's body and therefore covered with a first layer 14 of soft and comfortable material that does not irritate skin upon contact so it can be worn in a woman panty. First layer 14 prevents 15 direct contact between reagents that are provided in within device 10 and the adjacent skin. It should be noted that first layer 14 may be transparent so as to allow easy visual distinction of the colors formed in layers beneath it. Device 10 is further comprises with a supportive base layer 16 that can 20 support reagent carrier matrices 12 capable of carrying out the assays of interest. Reagent carrier matrices 12 are preferably an absorbent material that allows the liquid sample to move through the matrix. Reagent carrier matrices 12 should be inert with respect to the chemical reagents and should not alter the sample or the test results. 25 Optionally, reagent carrier matrices 12 can be made of many materials, for example: fiber-containing papers such as filter papers, woven and nonwoven fabrics, synthetic or modified natural polymers, sponge materials, cellulose, glass fiber, micro-porous membranes, and wood. Additional materials can be micro porous polymer materials such as styrene based 30 copolymer, latex based, cellulose based or cotton based matrices. The reagent carrier matrices can also be different in characteristics such as roughness, smoothness, softness, and hardness.
WO 2009/050711 PCT/IL2008/001371 18 It should be noted that in the manufacturing process, the reagent carrier matrices can be made from several layers, some of which carry different reagents in different areas of the test zone. Any combination of the supportive base layer and additional matrices carrying the indicators are 5 covered by the scope of the present invention and by no means limit the scope of the present invention. Beneath supportive base layer 16, a sticky backing layer 18 is provided and an adjacent outer protective layer 20 is also provided. Those two layers are similar in nature to the layers that are provided in protection panty shields. 10 Reagent carrier matrices 12 are organized preferably in groups wherein each group is provided with indicators capable of indicating one of the substances that were listed herein before. Following are examples of chemical reagents and methods of preparing the test zone for each: 15 Examples Creatinine test zone preparation Creatinine concentration in urine is normally about 10 times higher than its concentration in amniotic fluid. Creatinine dry test is made in two optional 20 ways: * Two reagent layers system that contains fixed creatinine sensitive dye that is placed on one matrix and a buffer that keeps the system in a relatively high pH value is placed on a second matrix. * One reagent layer system that contains a creatinine sensitive dye, 25 buffer, fixing agents all placed in one matrix. The creatinine sensitive dye can be one of dinitro derivatives such as: 3'5'-dinitrobenzoic acid, 2'4'-dinitrobenzoic acid, 3'5'- d initrobenzotrifluoride, 3'5'-dinitrobenzamide, 3'5'-dinitrobenzoyl- phenyl glycine, 3,5-dinitrohydroxyphenylpropionic acid. 30 The sensitive dye fixing agent preferably includes polymerized quaternary ammonium cations (quats) such as: polydiallyldimethylammoniumchloride (Poly DADMAC), WO 2009/050711 PCT/IL2008/001371 19 polymonoallyltrimethylammoniumchloride, polytrimethylaminoethylmethacrylatechloride, polyvinylbenzyltrimethylammoniumchloride, polyvinylmpthylpyridine- chloride. The buffer should be a strong base capable of keeping a stable pH in a 5 range of about 9 to 13.5. examples for such buffers are sodium metasilicate, sodium hydroxide, potassium hydroxide, calcium . hydroxide, sodium hydroxide-potassium chloride, potassium carbonate, glycine - sodium hydroxide, and sodium borate. Optionally, non volatile solid reagents are added to the sensitive dye in io order to improve the reaction. Two reaqent layers system; Example 1 Creatinine test indicator consisting of two reagent carrier matrices was mounted on the diagnostic device base layer. The first matrix (can be 15 Whatman filter paper or napkin paper) was impregnated with creatinine sensitive dye, 3'5'-dinitrobenzoic acid (dBA), and poly DADMAC (optional) as a fixing agent that were dissolved in water. The dBA stock solution was mixed in sodium carbonate buffer. A second reagent matrix was impregnated with Sodium Metasilicate buffer. After both reagent matrices were dry, the first 20 reagent matrix was laid on the second reagent matrix that was impregnated with Sodium Metasilicate buffer. Both dry reagent matrices were tightened on the base layer of the device. After a drop of vaginal secretions meet the dry reagent carrier matrix, a distinct color change will identify the liquid and indicate whether it contains 25 amniotic fluid or urine. Two reagent layers system: Example 2 Two reagent absorbent matrices were impregnated each in one solution, dried and were tightened on a base layer of the device. The first reagent 30 matrix was impregnated with solution 1 that consist of dBA (stock solution was dissolved in Sodium Hydroxide) as a creatinine sensitive dye, non volatile solid reagent and Poly DADMAC (optional) as a fixing agent. The second WO 2009/050711 PCT/IL2008/001371 20 reagent matrix was impregnated with solution 2 that include Sodium Hydroxide. Both reagent matrices were dried. Dry reagent matrix with solution 1 was placed above dry reagent matrix with solution 2 and both of them were tighten on the base layer of the device. 5 One reagent layers system: Example 1 As mentioned before, "one reagent layers system" has the same rational as the "two reagent layers system" but contains all the chemicals on one reagent carrier matrix. In both cases, the goal is differentiation between urine io and amniotic fluid using creatinine concentration. Creatinine test device was prepared from the same absorbent and support carriers as in the two reagent layers system. The reagent carrier matrix consists of a creatinine sensitive dye, non volatile solid reagent, a fixing agent (optional) and a buffer that was dried and mounted on the carrier matrix. 15 There was a preferable use of 3'5'-dinitrobenzoic acid (stock solution was made in acetonitrile) as a sensitive dye, Poly DADMAC as a fixing agent (optional) and Potassium Hydroxide (in ethyl alcohol solution) as a buffer. The reagents were dried all together and were ready for urine or amniotic fluid sample test. 20 One reagent layers system; Example 2 An emulsified solution of 3'5'-dinitrobenzoic acid, Poly DADMAC (optional), Styrene Acrylic acid, Sodium Metasilicate and a non volatile solid reagent was prepared. A thin layer of the emulsion was spread on a latex 25 based matrix, and dried. Dry matrices were tightening on the support base layer polymer of the device. Total Protein test zone preparation The concentration of total protein in amniotic fluid is normally about 15 30 times more than its concentration in urine. Interaction of proteins with substances, principally dyes and metal ions, causes a spectral change to a dye-metal ion solution. In implementing the device of the present invention, a WO 2009/050711 PCT/IL2008/001371 21 group of dyes and metal ions such as: 31,3"I,51,5" Tetrabromophenolsulfonephthalein, coomassie brilliant blue, Fast Green, Light Green, Pyrogallolsulfonephthalein (pyrogallol red), Pyrocatecholsulfonphthalein (Pyrocatechol Violet), 3',3"-Dibromo-5',5" 5 dichlorophenolsulfonephthalein, Fuchsin acid, 2,4-Dinitro-1 -naphthol (martius yellow), Copper, lead, Zink, Silver, phloxine B, congo red, ethyl orange and methyl orange can be used. The reagent carrier matrix of the total protein test device is an absorbent carrier that can be one of the matrices already mentioned, for example micro io porous polymer material such as styrene based copolymer, latex based, cellulose based or cotton based matrices. The reagent carrier matrix can be polymerized urethane-based compound (as described in U.S. Patent no. 5,124,266) incorporating an indicator reagent compound capable of interacting with proteins to produce a visually detectable response. 15 In order to reduce the variability due to urine density differences, the test solution may include a low pH potassium salt based buffer such as potassium citrate, potassium chloride, potassium sulfate, potassium iodate or potassium phosphate. 20 Total protein test: Example The total protein solution test comprises a combination of two solutions: the dye reagent solution and the buffer. For the dye solution, 3',3",5',5" Tetrabromophenolsulfonephthalein was used and was dissolved in a weak organic acid such as citric acid. The buffer, potassium citrate, was tittered with 25 the same weak organic acid to a low pH value of around 3.5. The dye solution was then diluted with the buffer solution in a wide ratio scale. After the dilution, a very thin layer of the resulting solution was spread on a reagent carrier matrix and dried. While a urine and amniotic fluid comes in contact with the reagents imbedded in the device, a distinct color reaction 30 can differentiate between them. PH test zone preparation WO 2009/050711 PCT/IL2008/001371 22 As mentioned herein before, the preparation is placed on an absorbent reagent carrier matrix of any type. The reagent matrix is impregnated with a pH indicator for the measurement of fluid pH. The urine pH may vary from 4.5 to 8 while the amniotic fluid pH ranges from 6.9 to 7.15 in late pregnancy. This 5 pH range can be check with one indicator or two different pH indicators; a low pH indicator and a middle pH indicator. According to their useful pH range, for the low pH, Methyl yellow, Methyl orange, Methyl red, Bromofhenol Blue, Tetrabromphenol blue or Bromcresol green can be used. For the middle pH range, Cresol Red, Nitrizine, 10 Bromthymol blue, Neutral red, Rosolic acid, a-Naphtholphthalein or phenol red can be used. pH test: Example Cresol Red was dissolved in water and was impregnated on 3M paper 15 (blotting paper ra- reeve angel*). After the material is fully impregnated, the matrix is dried. Alkaline phosphatase test zone preparation Alkaline phosphatase activity in amniotic fluid is much higher then in 20 normal urine. Therefore, this activity can be used to differentiate and identify amniotic fluid from urine in vaginal secretion by using a dry test by which direct contact with such secretions is resulted by a distinct and different color formation for the secretions. When drop of vaginal secretion meets the dry matrix reaction zone, a distinct color change will identify the secretion content 25 and indicate whether it contains amniotic fluid or urine. Alkaline phosphatase test: Example The composition of the reaction reagent matrix for the detection of Alkaline phosphatase contained dry buffered solution of Alkaline phosphates' 30 substrate such as p-nitrophenyl phosphate, indoxyl phosphate, 4 methylumbelliferyl phosphate and alpha-naphthyl-phosphate and may also contain sensitive indicators such as bromocresol green.
WO 2009/050711 PCT/IL2008/001371 23 Reference is now made to Figures 2 - 5 illustrating diagnostic device for adhering onto women panties in accordance with preferred embodiments of the present invention. All diagnostic devices shown in Figures 2-5 comprises a base layer 22 that includes layers similar to the layers that are shown in 5 Figure 1 that allows the device to be used in the panty of a women, adhered directly to the woman's panty or adhered onto a panty shield while the layer with the test zone, which will be explained herein after, is directly positioned beneath the vaginal canal of the woman. In order to view the device, the protective layer is removed from the drawings. Figure 2 illustrates a diagnostic io device 20 having test zones that are divided into five reagent carrier matrices 24-32 wherein each of the reagent carrier matrices is provided with diagnostic indicator that is capable of identifying a specific substance as elaborated herein before - e.g. creatinine test, protein test, alkaline phospatase test ect. Figure 3 illustrates a diagnostic device 40 having three distinct test 15 zones 12. Each zone is divided into five different reagent carrier matrices wherein each one is provided with different indicator capable of distinguishing between urine and amniotic fluid. Figure 4 illustrates a diagnostic device 50 similar to device 20 wherein different indicators are in 4 reagent carrier matrices 54-58. 20 Figure 5 illustrates a diagnostic device 60 having test zones 12, each having a reagent carrier matrices 62-68 provided with different indicators so as to distinguish between urine and amniotic fluid. As mentioned herein before, according to the present invention, the device may contain two or more reagent carrier matrices in lines, circles or 25 any other formation so at least two indicators are changed in their color so as to be able to clearly distinguish between the urine and the amniotic fluid. Reference is now made to Figures 6a-d illustrating diagnostic pads in accordance with preferred embodiments of the present invention. As mentioned herein before, a pad can be used in a way that it is pressed against 30 a regular wet panty shield or wet panties, as an example, so as to prevent contact between the skin and the pad. Basically, the pad is built similarly to the adhered one, however, there is no adherence layer on the pad.
WO 2009/050711 PCT/IL2008/001371 24 Figure 6a illustrates a pad 70 having a base layer 72 onto which different reagent carrier matrices 74-79 provided with different indicators. Each reagent carrier matrices is capable of identifying a certain substance as explained herein before. 5 Figure 6b illustrates a pad with base layer 82 onto which reagent carrier matrices 94-98 or 104-106 are arranged in different arrangement. Figures 6c and 6d illustrate additional embodiments of pads 90 and 100 provided with less reagent carrier matrices zones, respectively. Reference is now made to Figure 7 illustrating a veterinary diagnostic io pad in accordance with another preferred embodiment of the present invention. Veterinary device 120 is basically similar to the diagnostic device used for humans however, the figure shows an upper view of pad 120 in which the adhesive zone 122 is around the test zones 124. 15
Claims (27)
1. A dry diagnostic device for distinguishing between amniotic fluid and urine in female secretion, the dry diagnostic device comprising: 5 a base layer; at least two inert carrier matrices provided on said base layer; dry reagents provided on said at least two inert carrier matrices wherein said dry reagents are capable of forming a chemical reaction with substances in the female secretion so as to 10 visually distinguishing between the amniotic fluid and urine wherein said dry reagents in each of said at least two carrier matrices is capable of reacting with different substance of said substances.
2. The dry diagnostic device as claimed in Claim 1, wherein said at least 15 two carrier matrices are made of absorbent material selected from a group of materials such as fiber-containing papers, woven and nonwoven fabrics, synthetic or modified natural polymers, sponge materials, cellulose, glass fiber, micro-porous membranes, wood, micro porous polymer materials such as styrene based copolymer, latex 20 based, cellulose based or cotton based matrices.
3. The dry diagnostic device as claimed in Claim 1, wherein said dry reagents are capable of reacting with substances present in the amniotic fluid or in the urine, wherein the substances have 25 concentration markedly higher in one of the amniotic fluid or urine than their concentration in the former.
4. The dry diagnostic device as claimed in Claim 3, wherein said substances include substances such as creatinine, alkaline 30 phosphatase, total protein, urea, urobilinogen and blood. WO 2009/050711 PCT/IL2008/001371 26
5. The dry diagnostic device as claimed in Claim 1, wherein one of the dry reagents in one of said at least two carrier matrices is capable of reacting with creatinine. 5
6. The dry diagnostic device as claimed in Claim 5, wherein said one of the carrier matrices comprises two reagent layers; one of which contains creatinine sensitive dye fixed with a dye fixing agent and a second one containing a buffer capable of keeping said one of the test zones in a relatively high pH value. 10
7. The dry diagnostic device as claimed in Claim 3, wherein said one of the carrier matrices comprises a unique layer containing a creatinine sensitive dye, buffer, and dye fixing agent. 15
8. The dry diagnostic device as claimed in Claims 6 and 7, wherein said creatinine sensitive dye is selected from a group of dinitro derivatives such as 3'5'-dinitrobenzoic acid, 2'4'-dinitrobenzoic acid, 3'5' dinitrobenzotrifluoride, 3'5'-dinitrobenzamide, 3'5'-dinitrobenzoyl phenyl glycine, 3,5-dinitrohydroxyphenylpropionic acid. 20
9. The dry diagnostic device as claimed in Claim 6 and 7, wherein said dye fixing agent selected from polymerized quaternary ammonium cations (quats) such as polydiallyldimethylammoniumchloride, polymonoallyltrimethylammoniumchloride, 25 polytrimethylaminoethylmethacrylatechloride, polyvinylbenzyltrimethylammoniumchloride, polyvinylmpthylpyridine chloride.
10. The dry diagnostic device as claimed in Claim 6 and 7, wherein said 30 creatinine sensitive dye and said dye fixing agent are buffered so as to keep a stable pH in a range of about 9 to 13.5. WO 2009/050711 PCT/IL2008/001371 27
11. The dry diagnostic device as claimed in Claim 6 and 7, wherein a buffer is selected from a group of sodium metasilicate, sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium hydroxide-potassium chloride, potassium carbonate, glycine - sodium hydroxide, and sodium 5 borate.
12. The dry diagnostic device as claimed in Claim 1, wherein one of the dry reagents in one of the carrier matrices is capable of reacting with total protein. 10
13. The dry diagnostic device as claimed in Claim 12, wherein said one of the dry reagents is a dye selected from a group of 3',3",5',5" Tetrabromophenolsulfonephthalein, coomassie brilliant blue, Fast Green, Light Green, Pyrogallolsulfonephthalein (pyrogallol red), 15 Pyrocatecholsulfonphthalein (Pyrocatechol Violet), 3',3"-Dibromo-5',5" dichlorophenolsulfonephthalein, Fuchsin acid, 2,4-Dinitro-1 -naphthol (martius yellow) phloxine B, congo red, ethyl orange and methyl orange. 20
14. The dry reagent device as claimed in Claim 13, further comprising a buffer such as potassium citrate, potassium chloride, potassium sulfate, potassium iodate or potassium phosphate.
15. The dry diagnostic device as claimed in Claim 13, further comprising 25 metal ion selected from Copper, lead, Zink, Silver.
16. The dry diagnostic device as claimed in Claim 1, wherein one of the dry reagents in one of the carrier matrices is capable of reacting with alkaline phosphatase. 30
17. The dry diagnostic device as claimed in Claim 16, wherein said one of the dry reagents Alkaline phosphates' substrate selected from p- WO 2009/050711 PCT/IL2008/001371 28 nitrophenyl phosphate, indoxyl phosphate, 4-methylumbelliferyl phosphate and alpha-naphthyl-phosphate.
18. The dry diagnostic device as claimed in Claim 1, wherein one of said 5 dry reagents is a pH sensitive reagent.
19. The diagnostic device as claimed in Claim 1, wherein said dry reagents cannot exit the carrier matrices. 10
20. The dry diagnostic device as claimed in Claim 1, wherein said at least two carrier matrices are covered by a protective layer.
21. The dry diagnostic device as claimed in Claim 20, said protective layer is transparent. 15
22. The dry diagnostic device as claimed in Claim 20, wherein said protective layer can be made of a thin "one-way structure" membrane permeable to liquids flowing to said at least two carrier matrices and prevents flow of reagents outwardly from the device. 20
23. The dry diagnostic device as claims in Claim 1, wherein a sticky backing layer is provided beneath said base layer.
24. The dry diagnostic device as claimed in Claim 23, wherein said sticky 25 backing layer is adjacently provided with an outer protective layer.
25. The dry diagnostic device as claimed in Claim 1, wherein said at least two carrier reagent matrices are organized in substantially parallel lines. 30
26. The dry diagnostic device as claimed in Claim 1, wherein said at least two reagent carrier matrices are organized in concentric lines. WO 2009/050711 PCT/IL2008/001371 29
27. The dry diagnostic device as claimed in Claim 1, wherein said at least two reagent carrier matrices are surrounded by adhesive material so as to allow adhering the diagnostic device when said at least two test 5 zones are opposite a vaginal canal of a female animal.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99932707P | 2007-10-18 | 2007-10-18 | |
US60/999,327 | 2007-10-18 | ||
PCT/IL2008/001371 WO2009050711A2 (en) | 2007-10-18 | 2008-10-22 | A diagnostic device for identifying rupture of membrane during pregnancy |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2008313294A1 true AU2008313294A1 (en) | 2009-04-23 |
Family
ID=40567887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2008313294A Abandoned AU2008313294A1 (en) | 2007-10-18 | 2008-10-22 | A diagnostic device for identifying rupture of membrane during pregnancy |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP2198299A4 (en) |
JP (1) | JP2011501810A (en) |
KR (1) | KR20100098606A (en) |
AU (1) | AU2008313294A1 (en) |
BR (1) | BRPI0818779A2 (en) |
CA (1) | CA2703254A1 (en) |
MX (1) | MX2010004156A (en) |
WO (1) | WO2009050711A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL214096A (en) | 2011-07-14 | 2016-02-29 | Gideon Mor | System for detection of meconium in amniotic fluid |
JP5542888B2 (en) * | 2011-10-17 | 2014-07-09 | アークレイ株式会社 | Protein concentration evaluation method, analysis tool, and analyzer |
EP3129779B1 (en) * | 2014-04-10 | 2020-06-03 | Yale University | Methods and compositions for detecting misfolded proteins |
CN109613177B (en) | 2014-07-01 | 2021-08-20 | 科蒙森斯公司 | Diagnostic composition for identifying amniotic fluid |
CN108542596A (en) * | 2018-04-03 | 2018-09-18 | 顾勍 | Premature rupture of fetal membranes detects protection pad |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4774192A (en) * | 1987-01-28 | 1988-09-27 | Technimed Corporation | A dry reagent delivery system with membrane having porosity gradient |
US5662867A (en) * | 1991-12-09 | 1997-09-02 | Bayer Corporation | System for creatinine determination |
AUPM717694A0 (en) * | 1994-08-01 | 1994-08-25 | Sand Institute | A test strip for the rapid quantification of urinary calcium loss |
US5733787A (en) * | 1996-06-17 | 1998-03-31 | Bayer Corporation | Method for the detection of creatinine |
US6551842B1 (en) * | 1999-03-26 | 2003-04-22 | Idexx Laboratories, Inc. | Method and device for detecting analytes in fluids |
DE20001141U1 (en) * | 2000-01-24 | 2000-04-27 | Buzluhan Huelya | Women's panty liner, especially for pregnant women |
US6524864B2 (en) * | 2000-12-28 | 2003-02-25 | Aurora L. Fernandez Decastro | Test strip for simultaneous detection of a plurality of analytes |
WO2003001213A2 (en) * | 2001-06-25 | 2003-01-03 | Bayer Healthcare Llc | Total protein detection methods and devices at low ph |
US6921647B2 (en) * | 2001-07-19 | 2005-07-26 | Common Sense Ltd. | Secretion-monitoring article |
US20050131287A1 (en) * | 2003-12-16 | 2005-06-16 | Kimberly-Clark Worldwide, Inc. | Detection of premature rupture of the amniotic membrane |
-
2008
- 2008-10-22 MX MX2010004156A patent/MX2010004156A/en active IP Right Grant
- 2008-10-22 JP JP2010529502A patent/JP2011501810A/en active Pending
- 2008-10-22 BR BRPI0818779 patent/BRPI0818779A2/en not_active IP Right Cessation
- 2008-10-22 WO PCT/IL2008/001371 patent/WO2009050711A2/en active Application Filing
- 2008-10-22 CA CA2703254A patent/CA2703254A1/en active Pending
- 2008-10-22 EP EP08838980A patent/EP2198299A4/en not_active Withdrawn
- 2008-10-22 KR KR1020107010727A patent/KR20100098606A/en not_active Application Discontinuation
- 2008-10-22 AU AU2008313294A patent/AU2008313294A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2198299A2 (en) | 2010-06-23 |
WO2009050711A3 (en) | 2010-03-11 |
JP2011501810A (en) | 2011-01-13 |
KR20100098606A (en) | 2010-09-08 |
BRPI0818779A2 (en) | 2015-04-14 |
MX2010004156A (en) | 2011-04-13 |
CA2703254A1 (en) | 2009-04-23 |
EP2198299A4 (en) | 2010-09-29 |
WO2009050711A2 (en) | 2009-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5630936B2 (en) | A method for detecting diseases at high speed by identifying targets in human body fluids | |
AU2007282856B2 (en) | A test strip for lateral flow assays | |
US4960710A (en) | Device and method of assaying for trace mounts of proteins | |
US8712491B2 (en) | Measurement of an analyte on the skin using a hue angle | |
US20050131287A1 (en) | Detection of premature rupture of the amniotic membrane | |
US20110065139A1 (en) | diagnostic device for identifying rupture of membrane during pregnancy | |
US9144520B2 (en) | Noninvasive detection of meconium in amniotic fluid | |
CA2370739A1 (en) | Multiple diagnostic device for a woman's health | |
CA1338588C (en) | Composition and method of assaying liquids for specific gravity | |
EP0436897A2 (en) | Device and method of separating and assaying whole blood | |
US20130177485A1 (en) | Diagnostic device for identifying rupture of membrane during pregnancy | |
AU2008313294A1 (en) | A diagnostic device for identifying rupture of membrane during pregnancy | |
US5087575A (en) | Composition for determining trace amount of protein | |
AU674327B2 (en) | Diagnostic method for determining the susceptibility to delivery and reagent kit for use therefor | |
EP1419268B1 (en) | Secretion-monitoring article | |
WO1994024557A1 (en) | Article and method for detecting the presence of pathogens in excreta | |
AU2002354890A1 (en) | Diagnostic pad | |
JP2001289845A (en) | Diaper for urianalysis | |
CA2745309A1 (en) | A diagnostic device for identifying rupture of membrane during pregnancy | |
JP2022529552A (en) | Analysis system for body fluids and wound-related biomolecules | |
JP4470354B2 (en) | In vivo testing device for 1-100 UL samples | |
US10677792B2 (en) | System for detection of an analyte in a fluid | |
CN108776226A (en) | Early onset preeclampsia rapid screening test paper and kit | |
US20070249037A1 (en) | Monitoring of Vitamin K Nutritional Status |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |